122 related articles for article (PubMed ID: 21353137)
1. Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases.
Schellekens AF; Mulder SF; van Eijndhoven PF; Smilde TJ; van Herpen CM
Gen Hosp Psychiatry; 2011; 33(1):83.e1-3. PubMed ID: 21353137
[No Abstract] [Full Text] [Related]
2. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
[No Abstract] [Full Text] [Related]
3. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Garfield DH; Hercbergs A; Davis PJ
J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
[No Abstract] [Full Text] [Related]
4. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of sunitinib in hemodialysis.
Izzedine H; Etienne-Grimaldi MC; Renée N; Vignot S; Milano G
Ann Oncol; 2009 Jan; 20(1):190-2. PubMed ID: 18801884
[No Abstract] [Full Text] [Related]
6. Sunitinib-induced thrombotic microangiopathy.
Noronha V; Punatar S; Joshi A; Desphande RV; Prabhash K
J Cancer Res Ther; 2016; 12(1):6-11. PubMed ID: 27072203
[TBL] [Abstract][Full Text] [Related]
7. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
8. Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma.
Rolleman EJ; Weening J; Betjes MG
Nephrol Dial Transplant; 2009 Jun; 24(6):2002-3. PubMed ID: 19332867
[No Abstract] [Full Text] [Related]
9. Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma.
Vázquez S; León L; Fernández O; Lázaro M; Grande E; Aparicio L
Adv Ther; 2012 Mar; 29(3):202-17. PubMed ID: 22328304
[TBL] [Abstract][Full Text] [Related]
10. NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.
Yu DS; Wu CL; Ping SY; Huang YL; Shen KH
J Urol; 2014 Aug; 192(2):559-66. PubMed ID: 24423438
[TBL] [Abstract][Full Text] [Related]
11. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
14. [The safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) for treatment of metastatic renal cell carcinoma].
Togo Y; Shimatani K; Hanasaki T; Yo T; Nakanishi Y; Nagasawa S; Hashimoto T; Shiraishi Y; Taoka R; Suzuki T; Go S; Higuchi Y; Kanematsu A; Nojima M; Tsuchihashi K; Makino Y; Shimizu Y; Kanamaru S; Kono Y; Matsumoto K; Utsunomiya N; Ito N; Kawakita M; Yamamoto S
Hinyokika Kiyo; 2014 May; 60(5):209-14. PubMed ID: 24894855
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab + sunitinib: microangiopathic haemolytic anaemia. A serious drug interaction between 2 cancer drugs.
Prescrire Int; 2009 Aug; 18(102):165. PubMed ID: 19746526
[No Abstract] [Full Text] [Related]
16. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.
Bozas G; Roy A; Ramasamy V; Maraveyas A
Onkologie; 2010; 33(6):321-3. PubMed ID: 20523097
[TBL] [Abstract][Full Text] [Related]
17. Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices.
Schnadig ID; Hutson TE; Chung H; Dhanda R; Halm M; Forsyth M; Vogelzang NJ
Clin Genitourin Cancer; 2014 Dec; 12(6):413-21. PubMed ID: 25163396
[TBL] [Abstract][Full Text] [Related]
18. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
